Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
1.073
+0.185 (20.87%)
Nov 21, 2024, 3:09 PM EST - Market open
Verrica Pharmaceuticals Stock Forecast
VRCA's stock price has decreased by -74.72% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for VRCA stock have an average target of 7.33, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 583.39% from the current stock price of 1.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VRCA stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 2 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 6, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 5, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $11 → $2 | Buy → Hold | Downgrades | $11 → $2 | +86.46% | Nov 5, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +832.31% | Oct 21, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $13 → $11 | Buy | Maintains | $13 → $11 | +925.55% | Oct 4, 2024 |
Financial Forecast
Revenue This Year
11.45M
from 5.12M
Increased by 123.42%
Revenue Next Year
25.73M
from 11.45M
Increased by 124.76%
EPS This Year
-1.57
from -1.48
EPS Next Year
-0.70
from -1.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.4M | 67.5M | 114.8M | ||
| Avg | 11.4M | 25.7M | 53.2M | ||
| Low | 7.1M | 9.0M | 18.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 415.2% | 489.2% | 346.2% | ||
| Avg | 123.4% | 124.8% | 106.8% | ||
| Low | 37.7% | -21.6% | -29.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.43 | -0.32 | -0.03 | ||
| Avg | -1.57 | -0.70 | -0.38 | ||
| Low | -1.68 | -0.96 | -0.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.